[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,291,872
  • Shares Outstanding, K 2,029,198
  • Annual Sales, $ 43,078 M
  • Annual Income, $ 7,538 M
  • EBIT $ 10,759 M
  • EBITDA $ 13,810 M
  • 60-Month Beta 0.38
  • Price/Sales 2.38
  • Price/Cash Flow 8.41
  • Price/Book 4.36

Options Overview Details

View History
  • Implied Volatility 27.42% (+0.50%)
  • Historical Volatility 26.88%
  • IV Percentile 44%
  • IV Rank 24.46%
  • IV High 61.51% on 10/23/25
  • IV Low 16.39% on 12/08/25
  • Expected Move (DTE 4) 1.35 (2.71%)
  • Put/Call Vol Ratio 0.55
  • Today's Volume 4,395
  • Volume Avg (30-Day) 4,376
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 103,133
  • Open Int (30-Day) 80,197
  • Expected Range 48.46 to 51.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.28
  • Number of Estimates 6
  • High Estimate $1.35
  • Low Estimate $1.25
  • Prior Year $1.23
  • Growth Rate Est. (year over year) +4.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.71 +0.20%
on 05/11/26
59.57 -16.38%
on 04/14/26
-8.40 (-14.43%)
since 04/10/26
3-Month
49.71 +0.20%
on 05/11/26
61.69 -19.26%
on 02/18/26
-8.68 (-14.84%)
since 02/11/26
52-Week
35.45 +40.51%
on 07/17/25
61.69 -19.26%
on 02/18/26
+13.19 (+36.02%)
since 05/09/25

Most Recent Stories

More News
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

On-screen parenting duo stars in new, original video highlighting relatable parenting moments, educating viewers about meningococcal disease, also known as meningitis GSK’s Ask2BSure...

GSK.LN : 1,844.500 (+0.08%)
GSK : 49.81 (-1.19%)
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AZN : 181.86 (-0.54%)
ABBV : 202.78 (+0.61%)
GSK : 49.81 (-1.19%)
GSK's Vaccine Momentum Meets the HIV Patent Cliff This Week—Can Specialty Medicine Bridge the Gap?

Barchart Research What to Expect from GSK Earnings GSK Generated April 28, 2026 Current Price $54.47 EPS Estimate $$1.17 Consensus Rating Hold Average Move 4.32% GSK's Vaccine Momentum Meets the HIV Patent...

GSK : 49.81 (-1.19%)
3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

WEN : 6.76 (-7.40%)
INVA : 22.52 (-1.62%)
GSK : 49.81 (-1.19%)
NBR : 100.15 (+2.82%)
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *

GSK.LN : 1,844.500 (+0.08%)
GSK : 49.81 (-1.19%)
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas

BORAY : 2.8100 (-3.10%)
GSK.LN : 1,844.500 (+0.08%)
GSK : 49.81 (-1.19%)
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...

GSK.LN : 1,844.500 (+0.08%)
GSK : 49.81 (-1.19%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 49.81 (-1.19%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 1,844.500 (+0.08%)
GSK : 49.81 (-1.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 51.79
2nd Resistance Point 51.36
1st Resistance Point 50.58
Last Price 49.81
1st Support Level 49.37
2nd Support Level 48.94
3rd Support Level 48.16

See More

52-Week High 61.69
Fibonacci 61.8% 51.67
Last Price 49.81
Fibonacci 50% 48.57
Fibonacci 38.2% 45.48
52-Week Low 35.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.